Connect your AI

Anika Therapeutics ANIK Accrued liabilities

Accrued liabilities at other companies

AVN

AVNSAVNS

-$33.7M-128%

Other financials

Income statement

Revenue$32.6M+15.6%

Net income$3.3M+183%

EPS (diluted)$0.24—

Balance sheet

Cash & equivalents$38.4M-27.8%

Total debt$25.7M+1.2%

Total equity$137.3M-7.0%

Total assets$183.5M-2.2%

Cash flow

Operating cash flow-$684.0K-262%

CapEx$1.4M-1.2%

Free cash flow-$2.1M-28.8%

Valuation

Market cap$199.85M+23.0%

P/S1.7×-0.1×

Profitability

Net margin-3.4%-1.6pp

FCF margin0.5%—

Returns & leverage

Return on equity-2.9%-1.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.7×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Anika Therapeutics’s 8-K, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's accrued liabilities?: Anika Therapeutics (ANIK) reported accrued liabilities of $265K in Q2 2026.
How has Anika Therapeutics's accrued liabilities changed year-over-year?: Anika Therapeutics's accrued liabilities increased by 112.3% year-over-year, from -$2.16M to $265K.